Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study.

Claire Falandry,Béatrice Horard,Amandine Bruyas,Eric Legouffe,J Cretin,Jérôme Meunier,J. Alexandre,Valerie Delecroix,Michel Fabbro,Marie-Noëlle Certain,Raymonde Maraval-Gaget,Eric Pujade Lauraine,Eric Gilson,Gilles Freyer

Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study.

2015

Claire Falandry
Béatrice Horard
Amandine Bruyas
Eric Legouffe
J Cretin
Jérôme Meunier
J. Alexandre
Valerie Delecroix
Michel Fabbro
Marie-Noëlle Certain
Raymonde Maraval-Gaget
Eric Pujade Lauraine
Eric Gilson
Gilles Freyer

Purpose Age induces a progressive decline in functional reserve and impacts cancer treatments. Telomere attrition leads to tissue senescence. We tested the hypothesis that telomere length (TL) could predict patient vulnerability and outcome with cancer treatment.

Keywords:

Telomere Homeostasis
Ovarian cancer
Cancer
Senescence
Telomere
Pregnancy
Oncology
Carboplatin
Medicine
Biomarker (medicine)
Internal medicine
Risk factor
Adverse effect
Odds ratio

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations